Pharmacokinetics of ornidazole in neonates and infants after a single intravenous infusion
- 50 Downloads
The single dose pharmacokinetics of ornidazole has been evaluated in 12 neonates or infants (aged 1 to 42 weeks) after the infusion of 20 mg/kg over 20 min. Plasma disposition was described by a two-compartment open model. The distribution phase was short (T1/2 (1)=0.31 h) and was followed by an elimination phase (t1/2 (2)=14.67 h). The mean apparent volume of distribution was 0.96 l/kg−1. These results did not differ from data previous by reported in adults. Total plasma clearance was between 0.4 and 1.4 ml·min−1·kg−1. The plasma concentration 24 h after the infusion was 7.32 mg·l−1, which was above the minimum inhibitory concentration for clinically significant anaerobic bacteria. Based on the pharmacokinetic results and residual concentrations at 24 h, a single daily infusion of ornidazole 20 mg·kg−1 appears adequate for therapy in neonates and infants.
Key wordsornidazole neonates pharmacokinetics intravenous infusion
Unable to display preview. Download preview PDF.
- 1.Schwartz DE, Jeunet F (1976) Comparative studies of ornidazole and metronidazole in man. Chemotherapy 22: 19–29Google Scholar
- 2.Delion F, Thebault JJ, Singlas E (1985) Ornidazole: Une ou deux administrations par jour? J Pharm Clin 4: 301–307Google Scholar
- 3.Merdjan H, Bonnat C, Singlas E et al (1983) Measurement of ornidazole by high-performance liquid chromatography. J Chromatogr 273: 475–480Google Scholar
- 4.Johnston A, Woollard RC (1983) STRIPE: An interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods 9: 193–199Google Scholar
- 5.Palmu A, Renkonen OV, Aromaa U (1979) Ornidazole and anaerobic bacteria: in vitro sensitivity and effects on wound infections after appendectomy. J Infect Dis 139: 586–589Google Scholar
- 6.Vincent-Ballereau F, Lafaix CH (1982) Les 5 nitro-imidazoles dans le traitement et la prévention des infections à anaerobies Rev Med 4: 131–137Google Scholar
- 7.Wust J (1977) Susceptibility of anaerobic bacteria to metronidazole, ornidazole and tinidazole, and routine susceptibility testing by standardized methods. Antimicrob Chemother 11: 631–637Google Scholar